Harnessing predictive analytics for proactive drug safety monitoring: Trends in regulatory reporting, recalls and adverse event detection

Ensuring drug safety remains a critical concern in global healthcare systems as the volume of pharmaceuticals on the market expands and the complexity of therapeutic interventions increases. Traditional pharmacovigilance systems rely heavily on passive reporting mechanisms, which often lead to delayed detection of adverse events and reactive recall strategies. In this context, the integration of predictive analytics into drug safety monitoring offers a transformative pathway for proactive risk management. This study explores the evolving landscape of predictive analytics tools including machine learning algorithms, real-time signal detection, and pattern recognition frameworks that enhance the early identification of safety signals across distributed datasets, including electronic health records (EHRs), adverse event databases, and supply chain logs. We begin by reviewing the limitations of existing regulatory reporting systems and the rising frequency of pharmaceutical recalls over the past decade. We then investigate how predictive modeling enables near-real-time pharmacovigilance through the triangulation of clinical, social, and manufacturing data. Case studies of recent high-profile recalls are analyzed to demonstrate how earlier detection might have altered public health outcomes. Additionally, we highlight the role of regulatory agencies such as the FDA and EMA in fostering algorithmic accountability and real-world validation for AI-powered drug safety systems. By aligning predictive analytics with regulatory oversight and patient-centered design, this approach holds promise for mitigating health risks, enhancing post-market surveillance, and reducing the economic burden of drug-related harm. The paper concludes with recommendations for integrating these systems into current safety infrastructures and suggests pathways for future research in AI-driven pharmacovigilance.